CurrentBlue Cross Blue Shield - IowaPolicy 07.01.101

Urethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)

Governs coverage for use of urethral drug-coated balloon catheters (e.g., Optilume®) to treat obstructive urinary symptoms from anterior urethral strictures for Wellmark/Blue Cross Blue Shield - Iowa members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyUrethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)

Policy CodePolicy 07.01.101

Change TypeNo material changes

Effective DateApril 2024

Next Review Date

Key ActionDo not submit claims for urethral drug-coated balloon treatment without verifying coverage because the procedure is considered investigational and at risk for denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Dec 2021FDA PMA

83.2%1‑yr freedom from repeat intervention

77.8%2‑yr freedom from repeat intervention

80.8%Pooled recurrence-free rate

9.5%Complication rate

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Mar 2026Policy renewal

Coverage Criteria and Clinical Rationale

Investigational / Not covered

Covered when ALL of the following are met

Investigational determination: The use of a urethral drug-coated balloon for the treatment of obstructive urinary symptoms associated with urethral stricture(s) is considered investigational because the evidence is insufficient to determine the technology results in an improvement in net health outcomes.

Because the policy deems this investigational, the therapy is not covered under this policy.

Coverage considerations / trial-derived criteria

Evidence and guideline-informed considerations derived from clinical studies and society guidance

Typical trial-derived eligibility: Adult males with anterior (typically bulbar) urethral strictures under 3 cm in length (trial eligibility <3 cm; many analyses emphasize <2–3 cm), symptomatic with elevated IPSS and reduced Qmax, and with at least two prior endoscopic treatments (dilation, uncoated balloon dilation, or DVIU).see text

Eligibility features reflect ROBUST III trial entry criteria.

Comparators and place in care: Drug‑coated balloon (DCB) therapy has been compared to standard endoscopic management (uncoated balloon dilation and DVIU) in randomized trials; urethroplasty was not compared in these trials and remains a standard option for recurrent strictures.

Guideline statements (AUA, EAU) suggest offering DCBs for short (<3 cm) recurrent bulbar strictures after prior endoscopic failures when urethroplasty is not an option.

Evidence limitations relevant to coverage decisions: Randomized trial evidence shows improved short- to mid-term anatomical success and reduced need for repeat intervention versus endoscopic management, but long-term benefit beyond ~2–3 years is uncertain due to limited longer-term comparative data and participant drop-out; generalizability is limited because most trial participants had bulbar strictures and patients with strictures after urethroplasty were excluded from trials.

These limitations inform the investigational stance and potential exclusion of certain populations (e.g., post‑urethroplasty strictures).

Optilume® (a urethral drug‑coated balloon) is contraindicated in individuals with known hypersensitivity to paclitaxel or structurally related compounds and in patients who have certain urologic implants such as penile implants or artificial urinary sphincters, per the device regulatory information.

Evidence is limited for individuals with urethral strictures that developed after urethroplasty; these patients were excluded from the pivotal ROBUST III randomized trial and available data for this population are primarily from small single‑arm or retrospective series. Because comparative data versus urethroplasty are lacking, conclusions about effectiveness and durability in post‑urethroplasty strictures remain uncertain.

This document segment does not list additional explicit coverage exclusions beyond device contraindications and population limitations noted in the evidence sections.

Because available studies include a single RCT alongside systematic reviews and multiple single‑arm cohorts with generally short follow‑up and limited comparative data, the evidence is insufficient to determine that urethral drug‑coated balloon therapy improves net health outcomes for treatment of urethral strictures.

Long‑term net health benefit is uncertain: although durability and freedom from repeat intervention favor the drug‑coated balloon through 1–2 years in trials, longer‑term comparative follow‑up is limited and participant drop‑out in extended follow‑up reduces confidence in sustained benefit beyond two years.

No distinct “not medically necessary” phrasing is provided in this segment; the document communicates the coverage stance through the investigational determination and supporting evidence statements.

Billing and Coding

Codes table referencedmixed

No codes listed

Covered CPT CodesCPTCovered

52284

Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed.

HCPCSHCPCS

No code(s)

No HCPCS codes listed in this segment.

Place/Type of Servicemixed

Surgery	Type of Service: Surgery.
Outpatient	Place of Service: Outpatient.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior approval is not applicable for this investigational treatment. Providers should be aware that the use of a urethral drug-coated balloon (e.g., Optilume®) for treatment of obstructive urinary symptoms associated with urethral stricture(s) is considered investigational by this payer and is therefore not covered.

Affected procedure: urethral drug-coated balloon dilation (Optilume®) for urethral strictures
Coverage stance: Investigational / Not covered
Prior approval: Not applicable

Denial Risk

Denial Risk for Investigational Treatment

The policy deems treatment with a urethral drug-coated balloon (e.g., Optilume®) investigational. If providers submit claims or request pre-service review, include clear documentation of the procedure performed and rationale; however, by policy the service remains investigational and will be denied.

Background and Clinical Context

Urethral strictures are focal narrowing of the urethral lumen due to fibrosis from prior inflammation, trauma, instrumentation, or surgery and commonly present with obstructive lower urinary tract symptoms such as reduced urinary stream and incomplete bladder emptying. Short bulbar strictures are often initially managed with dilation, direct vision internal urethrotomy (DVIU), or urethroplasty, and adjunctive approaches such as a drug‑coated balloon (e.g., Optilume®) aim to reduce recurrence by delivering an antiproliferative agent (paclitaxel) to the urethral tissue at the time of mechanical dilation.

Definitions and Key Terms

Urethral drug-coated balloon definition

DefinitionA balloon catheter designed to mechanically dilate urethral strictures while transferring the antiproliferative drug paclitaxel from the balloon surface to the urethral tissue to reduce recurrence (example: Optilume®).

Primary purposeProvide a minimally invasive alternative to standard endoscopic management or urethroplasty for obstructive urinary symptoms from urethral stricture.

Drug deliveredPaclitaxel (coated on the balloon surface).

MechanismCombines mechanical dilation with local antiproliferative drug transfer to the urethral wall during cystourethroscopy.

Urethral stricture vs stenosis

Urethral stricture

Policy Revision History

March 2026Policy renewedLatest

Policy renewed following annual review.

March 2025Policy renewed

Policy renewed following annual review.

March 2024New medical policy created

Policy created (new medical policy).

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyUrethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)

Policy CodePolicy 07.01.101

Change TypeNo material changes

Effective DateApril 2024

Next Review Date

Key ActionDo not submit claims for urethral drug-coated balloon treatment without verifying coverage because the procedure is considered investigational and at risk for denial.

SourceLink

On This Page

Provider action: Treatment with a urethral drug-coated balloon is considered investigational and may be denied
Provider action: If submitting, include detailed clinical documentation of prior treatments and diagnostic findings

Documentation Required

Document diagnostic evaluation and prior therapies thoroughly. Required supporting documentation includes evidence of diagnosis (e.g., cystoscopy, retrograde urethrography, ultrasound urethrography), symptom severity measures (e.g., IPSS), uroflowmetry results, prior endoscopic treatments (dilation, DVIU) or other comparators, and rationale for selecting the investigational procedure.

Required diagnostic documentation: urethra-cystoscopy, voiding cystourethrography, ultrasound urethrography, or retrograde urethrography
Required clinical outcome documentation: IPSS score, uroflowmetry (Qmax), stricture diameter assessments, and record of prior endoscopic/medical therapies

Note

Prior Treatment Documentation

The policy references typical prior treatment options (e.g., urethral dilation, DVIU, urethroplasty) and comparators (uncoated balloon dilation, endoscopic management, urethroplasty). Include documentation of these prior treatments and number of prior endoscopic failures when applicable.

Typical prior treatments: urethral dilation (uncoated), direct visual internal urethrotomy (DVIU), urethroplasty
Comparator treatments: serial dilation with urethral sounds, uncoated balloon dilation, DVIU, urethroplasty

Note

Limitations Not Explicitly Stated

Section content does not explicitly state other administrative limitations or exception pathways in this portion of the policy. Providers seeking exceptions or exploring coverage for specific cases should contact the payer's medical policy or provider services for guidance prior to performing the procedure.

Provider action: Not explicitly stated in this portion of the policy — contact payer for exception or appeals process

Billing Rule

Billing and Coding

Use the listed CPT code when reporting this procedure. Claims that do not use the specific CPT code listed in the policy may be subject to coding-related denials or manual review.

Reported CPT: 52284 — Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed
Provider action: Claims that do not use the listed CPT code may be denied or audited

Narrowing of the anterior urethra caused by chronic fibrosis from surgery, instrumentation, trauma, cancer treatment, or inflammation.

Urethral stenosisNarrowing of the posterior urethra (termed stenosis rather than stricture).

Common symptomsReduced urinary stream, incomplete bladder emptying, increased post-void residual, urinary spraying, painful urination; symptoms may overlap with infection.

Urethral drug-coated balloon (DCB) — short definition

Short definitionA urethral balloon device coated with an antiproliferative drug (eg, paclitaxel) intended to dilate urethral strictures and reduce recurrence by delivering drug to the urethral tissue.

Use settingApplied during cystourethroscopy as a treatment alternative to uncoated balloon dilation, endoscopic management, or urethroplasty.

Example deviceOptilume® (a paclitaxel-coated urethral balloon).

Population of interest

Population of interestIndividuals with obstructive urinary symptoms associated with anterior urethral stricture.

Typical clinical featuresSymptoms such as reduced urinary stream, incomplete emptying, and elevated post-void residual; confirmed anterior urethral narrowing.

Intended recipientsPatients considered for minimally invasive alternatives to dilation, DVIU, or urethroplasty (often adults with bulbar/ anterior strictures).

Optilume — device-specific definition

Device identificationOptilume® — a urethral drug-coated balloon catheter that delivers paclitaxel during cystourethroscopy with mechanical urethral dilation for treatment of urethral stricture.

Procedure contextDelivered during cystourethroscopy and mechanical dilation as a single-use balloon catheter to transfer paclitaxel to the urethral wall.

Therapeutic intentReduce stricture recurrence following dilation by local antiproliferative drug delivery.

Regulatory referenceReferenced in FDA Summary of Safety and Effectiveness Data for Optilume (see policy references).